NZ701038A - Treating acute decompensated heart failure with relaxin - Google Patents

Treating acute decompensated heart failure with relaxin

Info

Publication number
NZ701038A
NZ701038A NZ701038A NZ70103809A NZ701038A NZ 701038 A NZ701038 A NZ 701038A NZ 701038 A NZ701038 A NZ 701038A NZ 70103809 A NZ70103809 A NZ 70103809A NZ 701038 A NZ701038 A NZ 701038A
Authority
NZ
New Zealand
Prior art keywords
heart failure
relaxin
treating acute
decompensated heart
acute decompensated
Prior art date
Application number
NZ701038A
Other languages
English (en)
Inventor
Martha Jo Whitehouse
Gad Cotter
Elaine Unemori
Sam L Teichman
Dennis R Stewart
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Priority claimed from NZ622598A external-priority patent/NZ622598A/en
Publication of NZ701038A publication Critical patent/NZ701038A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ701038A 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin NZ701038A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
NZ622598A NZ622598A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin

Publications (1)

Publication Number Publication Date
NZ701038A true NZ701038A (en) 2016-01-29

Family

ID=40834101

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ701038A NZ701038A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin
NZ598709A NZ598709A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin
NZ589009A NZ589009A (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with h2 relaxin

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ598709A NZ598709A (en) 2008-05-16 2009-05-15 Treating acute decompensated heart failure with relaxin
NZ589009A NZ589009A (en) 2008-05-16 2009-05-15 Treating dyspnea associated with acute heart failure with h2 relaxin

Country Status (30)

Country Link
US (7) US8053411B2 (enExample)
EP (2) EP2288373B1 (enExample)
JP (4) JP5651586B2 (enExample)
CN (3) CN103212063B (enExample)
AR (1) AR071810A1 (enExample)
AU (1) AU2009246114B2 (enExample)
BR (1) BRPI0913011A2 (enExample)
CA (1) CA2724540C (enExample)
CR (1) CR11749A (enExample)
CY (1) CY1116925T1 (enExample)
DK (1) DK2288373T3 (enExample)
EA (2) EA022948B1 (enExample)
ES (1) ES2546287T3 (enExample)
GB (2) GB2462221B (enExample)
HK (1) HK1202054A1 (enExample)
HR (1) HRP20150845T1 (enExample)
HU (1) HUE025483T2 (enExample)
IL (3) IL208992A (enExample)
MA (1) MA32389B1 (enExample)
MX (1) MX2010012450A (enExample)
MY (2) MY159803A (enExample)
NZ (3) NZ701038A (enExample)
PL (1) PL2288373T3 (enExample)
PT (1) PT2288373E (enExample)
SG (2) SG191587A1 (enExample)
SI (1) SI2288373T1 (enExample)
TW (1) TWI386202B (enExample)
UA (1) UA99953C2 (enExample)
WO (1) WO2009140659A2 (enExample)
ZA (1) ZA201007449B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure
MX336145B (es) * 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
US20130053318A1 (en) 2010-03-10 2013-02-28 Parry Laura Modulating aquaporins with relaxin
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9382305B2 (en) * 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
EA030354B1 (ru) * 2012-10-26 2018-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906019B1 (en) 2019-01-04 2025-11-26 SQ Innovation AG Pharmaceutical compositions of furosemide
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
CA3128033A1 (en) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
AU2023332056A1 (en) 2022-08-31 2025-03-13 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (en) * 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
WO1995003822A2 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
DE69624925T2 (de) 1995-08-15 2003-09-04 Connetics Corp., Palo Alto Verwendung von relaxin zur stimulierung der angiogenese
DE60128540T2 (de) 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
MX336145B (es) 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure

Also Published As

Publication number Publication date
US20150320834A1 (en) 2015-11-12
DK2288373T3 (en) 2015-09-28
TW200948353A (en) 2009-12-01
HK1139051A1 (en) 2010-09-10
MX2010012450A (es) 2011-03-21
HK1187550A1 (zh) 2014-04-11
PT2288373E (pt) 2015-10-19
US9205132B2 (en) 2015-12-08
US8053411B2 (en) 2011-11-08
US20130210730A1 (en) 2013-08-15
IL208992A (en) 2013-09-30
EP2829280A1 (en) 2015-01-28
JP2011520918A (ja) 2011-07-21
CN106177914A (zh) 2016-12-07
CN103212063B (zh) 2015-07-22
WO2009140659A3 (en) 2010-07-22
HUE025483T2 (en) 2016-02-29
GB2459983B (en) 2010-04-28
US20120040902A1 (en) 2012-02-16
HRP20150845T1 (hr) 2015-11-06
US20130116181A1 (en) 2013-05-09
IL228244A (en) 2016-10-31
CY1116925T1 (el) 2017-04-05
US9579363B2 (en) 2017-02-28
US9066916B2 (en) 2015-06-30
HK1202054A1 (en) 2015-09-18
IL247351A0 (en) 2016-09-29
UA99953C2 (uk) 2012-10-25
CA2724540C (en) 2014-07-08
JP2016053040A (ja) 2016-04-14
MY158327A (en) 2016-09-30
CA2724540A1 (en) 2009-11-19
AU2009246114B2 (en) 2013-01-31
EA022948B1 (ru) 2016-03-31
BRPI0913011A2 (pt) 2019-09-03
WO2009140659A2 (en) 2009-11-19
TWI386202B (zh) 2013-02-21
PL2288373T3 (pl) 2015-11-30
AR071810A1 (es) 2010-07-14
GB0918132D0 (en) 2009-12-02
EP2288373A2 (en) 2011-03-02
NZ598709A (en) 2013-09-27
GB2459983A (en) 2009-11-18
JP2013040174A (ja) 2013-02-28
CR11749A (es) 2011-02-11
AU2009246114A1 (en) 2009-11-19
HK1151229A1 (en) 2012-01-27
IL208992A0 (en) 2011-01-31
GB2462221A (en) 2010-02-03
US8415301B2 (en) 2013-04-09
SG10201609580YA (en) 2016-12-29
US20120040903A1 (en) 2012-02-16
US20170151311A1 (en) 2017-06-01
JP5638044B2 (ja) 2014-12-10
GB0908432D0 (en) 2009-06-24
US8372809B2 (en) 2013-02-12
GB2462221B (en) 2010-09-01
EP2288373B1 (en) 2015-06-24
JP5651586B2 (ja) 2015-01-14
SG191587A1 (en) 2013-07-31
CN103212063A (zh) 2013-07-24
EA201500552A1 (ru) 2016-07-29
ES2546287T3 (es) 2015-09-22
JP2015013870A (ja) 2015-01-22
EA201001771A1 (ru) 2011-06-30
US20100048475A1 (en) 2010-02-25
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
HK1140693A1 (en) 2010-10-22
SI2288373T1 (sl) 2015-12-31
MY159803A (en) 2017-02-15
CN102036679A (zh) 2011-04-27
ZA201007449B (en) 2011-06-29
JP5875646B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
IL247351A0 (en) A pharmaceutically active human H2 relaxin for use as a drug in the treatment of dyspnea associated with severe heart failure
IL213359A0 (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
NZ588033A (en) Methods of treating a mif-mediated disorder
PL3338791T3 (pl) Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
WO2009065093A3 (en) Use of stem cells for wound healing
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
NZ603602A (en) Compositions and methods for treatment of kidney disorders
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
TR201900240T4 (tr) Gece idrara çıkışları azaltmak için desmopresin.
EA201170873A1 (ru) Безопасное введение десмопрессина
MX2010011401A (es) Asociacion de la dronedarona con al menos un diuretico, su aplicacion en terapeutica.
JO2748B1 (en) New therapeutic use to treat leukemia
TN2010000249A1 (en) New medical use of 3-(2,2,2-trimethylhydrazinium ) propionate salts
NZ622598A (en) Treating acute decompensated heart failure with relaxin
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
IL216984A0 (en) Cloning, yeast expression, purification and biological activity of the extension region of the soybean 7s globulin alfa' subunit involved in hep g2 cell cholesterol homeostasis
MX337705B (es) Uso terapeutico de conjugados proteina-polimero.
贾雪 et al. The Effect of Comprehensive Rehabilitation System on the Treatment of 54 Earthquake Patients with Lower Limb Fracture
UA41106U (ru) Способ лечения гипостатической пневмонии у больных с хронической сердечной недостаточностью
ITGE20090003U1 (it) Trattamento estetico abbronzante, lampade per l'attuazione di detto trattamento e struttura portante di supporto dell'utente per dispositivi di trattamento estetico mediante irraggiamento

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 MAY 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20160512

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAY 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20160512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAY 2018 BY CPA GLOBAL

Effective date: 20170418

LAPS Patent lapsed